Vettek

Vettek is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of advanced solid tumors. The company's core technology utilizes targeted superantigens, specifically Staphylococcal Enterotoxin B (SEB), to induce a potent and systemic anti-tumor immune response. By leveraging the unique ability of superantigens to activate a large percentage of the T-cell repertoire, Vettek aims to overcome the immunosuppressive microenvironment of refractory cancers. Founded by Dr. David S. Terman, the company has advanced its lead programs into early-phase clinical trials, demonstrating the potential of superantigens to treat various malignancies, including lung and breast cancer.